{"id":"ivermectin-400-g-kg","safety":{"commonSideEffects":[{"rate":null,"effect":"Mazzotti reaction (fever, pruritus, rash, lymphadenitis)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3932957","moleculeType":"Small molecule","molecularWeight":"459.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin is a macrocyclic lactone that selectively activates chloride channels in invertebrate nervous and muscular systems, leading to hyperpolarization, paralysis, and death of susceptible parasites. It has high selectivity for invertebrate channels over mammalian GABA receptors due to structural differences. The drug is widely used as an antiparasitic agent against nematodes, arthropods, and certain other parasites.","oneSentence":"Ivermectin binds to glutamate-gated chloride channels in parasites and some insects, causing paralysis and death of the organism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:30.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parasitic infections including onchocerciasis (river blindness)"},{"name":"Lymphatic filariasis"},{"name":"Strongyloidiasis"},{"name":"Scabies"},{"name":"Lice infestations"}]},"trialDetails":[{"nctId":"NCT07487805","phase":"PHASE2","title":"Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-07","conditions":"Solid Tumor, Adult","enrollment":80},{"nctId":"NCT04311671","phase":"PHASE3","title":"Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2021-05-03","conditions":"Onchocerciasis","enrollment":12979},{"nctId":"NCT04410406","phase":"PHASE3","title":"Moxidectin for LF, Cote d'Ivoire (DOLF)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-20","conditions":"Lymphatic Filariasis","enrollment":164},{"nctId":"NCT04332068","phase":"PHASE2","title":"Ivermectin Safety in Small Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-11-18","conditions":"Scabies","enrollment":240},{"nctId":"NCT06070116","phase":"PHASE2","title":"Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-04-05","conditions":"Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular","enrollment":300},{"nctId":"NCT06404333","phase":"PHASE2","title":"Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2025-02-25","conditions":"Scabies","enrollment":13},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT06184399","phase":"PHASE2","title":"Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2024-06-05","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":260},{"nctId":"NCT07045493","phase":"PHASE2","title":"Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh","status":"ENROLLING_BY_INVITATION","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-07-10","conditions":"Soil Transmitted Helminth (STH) Infections","enrollment":110},{"nctId":"NCT04700423","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2021-03-01","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":536},{"nctId":"NCT04188301","phase":"PHASE2","title":"Safety and Efficacy of IDA for Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-06","conditions":"Onchocerciasis","enrollment":154},{"nctId":"NCT06037876","phase":"PHASE3","title":"Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2023-10-09","conditions":"Trichuriasis","enrollment":161},{"nctId":"NCT03527732","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2018-09-09","conditions":"Trichuriasis","enrollment":1673},{"nctId":"NCT04726969","phase":"PHASE3","title":"Efficacy and Safety of MOX/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2021-06-15","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":255},{"nctId":"NCT05894538","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2022-02-16","conditions":"Covid19","enrollment":1459},{"nctId":"NCT02841215","phase":"PHASE3","title":"Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-10-11","conditions":"Gale, Severe Forms of Scabies, Oral Parasitic Drug","enrollment":133},{"nctId":"NCT05736861","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":1800},{"nctId":"NCT02974049","phase":"NA","title":"Lymphatic Filariasis (LF) in Ivory Coast","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2015-01","conditions":"Lymphatic Filariasis","enrollment":189},{"nctId":"NCT04602507","phase":"PHASE2","title":"Ivermectin in Adults With Severe COVID-19.","status":"TERMINATED","sponsor":"CES University","startDate":"2020-12-10","conditions":"Covid19, Severe Acute Respiratory Syndrome","enrollment":75},{"nctId":"NCT05040724","phase":"PHASE3","title":"Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19","status":"UNKNOWN","sponsor":"Raincy Montfermeil Hospital Group","startDate":"2021-05-28","conditions":"To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care","enrollment":200},{"nctId":"NCT03432442","phase":"PHASE2","title":"Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2018-09-04","conditions":"Dengue Hemorrhagic Fever","enrollment":24},{"nctId":"NCT02078024","phase":"PHASE3","title":"Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-06","conditions":"Onchocerciasis","enrollment":375},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":"Trachoma, Yaws, Lymphatic Filariases","enrollment":20000},{"nctId":"NCT02509481","phase":"PHASE2, PHASE3","title":"Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study","status":"COMPLETED","sponsor":"Colorado State University","startDate":"2015-06","conditions":"Malaria, Lymphatic Filariasis","enrollment":2712},{"nctId":"NCT01975441","phase":"PHASE2","title":"Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-05","conditions":"Lymphatic Filariasis","enrollment":182},{"nctId":"NCT02045069","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Ivermectin Against Dengue Infection","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2014-02","conditions":"Dengue Fever","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ivermectin 400 µg/kg","genericName":"Ivermectin 400 µg/kg","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin binds to glutamate-gated chloride channels in parasites and some insects, causing paralysis and death of the organism. Used for Parasitic infections including onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}